Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service

Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases


Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered a collaboration agreement with Daiichi Sankyo (TSE: 4568) for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.

Under the terms of the agreement, Confo will lead the discovery process deploying its GPCR platform to generate lead series of small molecule compounds. Daiichi Sankyo has an exclusive option to acquire a worldwide exclusive license for the resulting compounds and advance them towards clinical development and commercialization. Confo has the potential to receive upfront payments, development and commercial milestones totaling EUR 168M and royalties.

"Daiichi Sankyo has historically been at the forefront of leveraging innovative technologies to develop novel medicines. We are excited by this collaboration in which we will be using Confo's expertise and platform to pursue a previously undruggable GPCR target in an area of high unmet medical need," said Cedric Ververken, CEO of Confo Therapeutics. "As we expand the scope of our internal drug discovery and development efforts, we look forward to continuing to enter partnerships with leading innovators to create new therapeutic options for patients."

About Confo Therapeutics

Confo Therapeutics' unparalleled technology stabilizes functional conformations of GPCRs (G-protein coupled receptors), thereby enabling the discovery of chemical or biological ligands that are conformationally selective. This platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the vision of transforming therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of VIB-VUB (Vrije Universiteit Brussel) in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium.

For more information, visit www.confotherapeutics.com


These press releases may also interest you

at 09:00
Guidewire announced that Guidewire PartnerConnect Consulting and Global Premier partner, Ernst & Young LLP (EY), has achieved the global Migration Acceleration Specialization. Partners who have earned this specialization have demonstrated the...

at 09:00
The Commerce Casino & Hotel, home to the largest poker room in the world, proudly announces an exciting partnership with the richest, most prestigious, and longest-running poker series ? the World Series of Poker® (WSOP®). This collaboration...

at 09:00
The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp , a global leader of innovative diagnostic and biopharma laboratory services, to serve as its...

at 09:00
Rex 3 recently opened its doors to students from Florida Atlantic University (FAU) for Rex 3's 11th Annual 101 Printing Tour, reinforcing its commitment to community engagement and education in the printing industry. This tour provided students with...

at 09:00
GigaMedia Limited today announced its unaudited financial results for the fourth quarter and full year of 2023. Highlights For 2023, GigaMedia reported revenues of $4.3 million, with a gross profit of $2.4 million, an operating loss of $3.2 million...

at 09:00
Yardi® is proud to sponsor the 2024 Manufactured Housing Institute (MHI) Congress & Expo, April 3-4, at the iconic MGM Grand in Las Vegas. At the exhibit hall attendees can explore the newest product innovations, accessible April 3, from 1 p.m. to...



News published on and distributed by: